☰

Charles Raison - Publications

Affiliations: 
Psychiatry and Behavioral Sciences Emory University, Atlanta, GA 
Area:
Physiological causes of depression in the medically ill
Tree Info Grants Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Tyler MP, Wright BJ, Beaton R, Monger K, Raison CL, Lowry CA, Evans L, Hale MW. Severity of depressive symptoms moderates the sympathoinhibitory effect of local skin warming following exposure to a social stressor. Psychoneuroendocrinology. 159: 106420. PMID 37866124 DOI: 10.1016/j.psyneuen.2023.106420  0.311
2023 Flux MC, Smith DG, Allen JJB, Mehl MR, Medrano A, Begay TK, Middlemist BH, Marquart BM, Cole SP, Sauder CJ, Lowry CA, Raison CL. Association of plasma cytokines and antidepressant response following mild-intensity whole-body hyperthermia in major depressive disorder. Translational Psychiatry. 13: 132. PMID 37085494 DOI: 10.1038/s41398-023-02402-9  0.31
2021 Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Translational Psychiatry. 11: 58. PMID 33462203 DOI: 10.1038/s41398-020-01164-y  0.303
2018 Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain, Behavior, and Immunity. PMID 30102967 DOI: 10.1016/j.bbi.2018.08.009  0.315
2017 Raison C, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-Reactive Protein Effects In Patients With Bipolar Depression Treated With Lurasidone: An Exploratory Analysis Of A Placebo-Controlled Trial Frontiers in Psychiatry. 8. DOI: 10.3389/Conf.Fpsyt.2017.48.00029  0.325
2017 Raison C. 419. Inflammation in Treatment Resistant Depression: Challenges and Opportunities Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.903  0.349
2016 Janssen CW, Lowry CA, Mehl MR, Allen JJ, Kelly KL, Gartner DE, Medrano A, Begay TK, Rentscher K, White JJ, Fridman A, Roberts LJ, Robbins ML, Hanusch KU, Cole SP, ... Raison CL, et al. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder: A Randomized Clinical Trial. Jama Psychiatry. PMID 27172277 DOI: 10.1001/Jamapsychiatry.2016.1031  0.305
2016 Mascaro JS, Kelley S, Darcher A, Negi LT, Worthman C, Miller A, Raison C. Meditation buffers medical student compassion from the deleterious effects of depression Journal of Positive Psychology. 1-10. DOI: 10.1080/17439760.2016.1233348  0.322
2015 Felger JC, Haroon E, Woolwine BJ, Raison CL, Miller AH. Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiology & Behavior. PMID 26703235 DOI: 10.1016/j.physbeh.2015.12.013  0.311
2014 Raison CL. Inflammatory depression: a trifecta of trouble. The Journal of Clinical Psychiatry. 75: 663-4. PMID 25004190 DOI: 10.4088/JCP.14ac09217  0.301
2013 Raison CL, Miller AH. Role of inflammation in depression: implications for phenomenology, pathophysiology and treatment. Modern Trends in Pharmacopsychiatry. 28: 33-48. PMID 25224889 DOI: 10.1159/000343966  0.338
2013 Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Molecular Psychiatry. 18: 15-37. PMID 22290120 DOI: 10.1038/Mp.2012.2  0.362
2012 Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 137-62. PMID 21918508 DOI: 10.1038/npp.2011.205  0.338
2012 Raison C, Rutherford R, Woolwine B, Shuo C, Schettler P, Drake D, Haroon E, Miller A. 176. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation Brain, Behavior, and Immunity. 26: S49. DOI: 10.1016/J.Bbi.2012.07.200  0.382
2011 Raison CL, Miller AH. Is depression an inflammatory disorder? Current Psychiatry Reports. 13: 467-75. PMID 21927805 DOI: 10.1007/s11920-011-0232-0  0.323
2010 Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Archives of General Psychiatry. 67: 1211-24. PMID 21135322 DOI: 10.1001/archgenpsychiatry.2010.161  0.322
2009 Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry. 65: 732-41. PMID 19150053 DOI: 10.1016/j.biopsych.2008.11.029  0.363
2007 Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology & Therapeutics. 25: 1163-74. PMID 17451562 DOI: 10.1111/j.1365-2036.2007.03316.x  0.308
2006 Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology. 27: 24-31. PMID 16316783 DOI: 10.1016/j.it.2005.11.006  0.348
2003 Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biological Psychiatry. 54: 283-94. PMID 12893104 DOI: 10.1016/S0006-3223(03)00413-X  0.312
2002 Raison CL, Marcin M, Miller AH. Antidepressant treatment of cytokine-induced mood disorders. Acta Neuropsychiatrica. 14: 336-43. PMID 26984579 DOI: 10.1034/j.1601-5215.2002.140607.x  0.316
Show low-probability matches.